In a statement, the company said AstraZeneca has shown no evidence of an increased risk of pulmonary embolism, deep vein thrombosis or thrombosis subpoena in any defined age group, gender batch or in any particular country, the drugmaker added 37 blood related incidents have been reported so far, which it says is similar across other licensed covid 19 vaccines.
在一份聲明中,該公司表示,阿斯利康沒有顯示出任何證據表明在任何確定的年齡組,性別批次或在任何特定的國家,肺栓塞,深靜脈血栓或血栓傳票的風險增加,該製藥商補充說,到目前為止,已經有37起血液相關事件的報告,它說,在其他許可的covid 19疫苗中,這是類似的。